Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > GI drugs > Flashcards

GI drugs Flashcards

1
Q

Antibiotics given to fight H. pylori

A

Amoxicillin-preferre
Carithromycin- increasing resistance
Metronidazole-alternative for allergy
Tetracycline-for quadruple therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MOA of bismuth subsalicylate

A

antibacterial activity against H. pylori
binds E. coli enterotoxins
forms a barrier
anti-secretory and anti-inflammatory activities of salicylate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Therapeutic use of bismuth subsalicylate

A

PUD, diarrhea, nausea and cramping

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Adverse effects of bismuth subsalicylate

A

harmless black discoloration of stool and tongue, salicylism at high doses (tinnitus) Reye’s syndrome, use with caution in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antacid prototypes

A

magnesium hydroxide and aluminum hydroxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MOA of antacids

A

raise stomach pH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pharmacokinetics of antacids

A

1-2 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differences between Mg and Al hydroxide

A

Mg2+ -diarrhea due to peristaltic stimulation, Al smooth muscle relaxation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Therapeutic use of antacids

A

largely replaced by more effective, mild symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Drug interactions of antacids

A

can interfere with absorption of other drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prototype histamine receptor antagonists

A

cimetidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of histamine receptor antagonists

A

blocks acid secretion from parietal cells stimulated by histamine, highly selective for H2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Therapeutic use of H2R antagonists

A

supress total acid secretion by 70%, most effective in suppressing nocturnal acid secretion
Slower onset and longer duration than antacids, prophylactic
Tolerance can develop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adverse reactions of H2R antagonists

A

edocrine effects- loss of libido, impotence and gynocomastia
CNS effects- rare, in elderly with decreased liver/kidney function
Pneumonia-increased bacterial colonization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug interactions with H2R antagonists

A

cimetidine inhibits multiple cyp isoforms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prototype PPI

A

omeprazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

MOA of PPIs

A

irreversibly inhibits H+, K+ ATPase that are active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pharmacokinetics of PPI

A

30 min before meals, reduces acid secretion by 95%, effects persist for 2-3 days
Enteric coated to get to small intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Metabolism of PPIs

A

hepatic metabolism by CYPs, asian variant correlates with slow metabolism, dose reduction in patients with hepatic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Therapeutic uses of PPI

A

PUD, GERD, Zollinger-Ellison syndrome, NSAIDs associated ulcers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Adverse reactions of PPIs

A

nausea, abdominal pain, constipation/diarrhea, flatulence
pneumonia
fractures due to decreased Ca+ absorption
rebound hypersecretion upon discontinuation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Drug interactions with PPIs

A

warfarin, diazepam, cyclosporine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Mucosal protective agent prototype

A

sucralfate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

MOA of sucralfate

A

forms a gel at low pH, binds necrotic tissue forming a barrier to acid and pepsin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Therapeutic use of sucralfate

A

duodenal and stress ulcers, stomach pH not increased, does not increase pneumonia risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Adverse reactions of sucralfate

A

constipation, reduced absorption of other drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

PGE1 analog prototype

A

misoprostol

28
Q

MOA of misoprostol

A

reduces acid secretion from parietal cells by simulating PGs

29
Q

Therapeutic uses of misoprostol

A

NSAIDS patients, contraindicated in pregnancy (can induce abortions)

30
Q

Adverse effects of misoprostol

A

dose dependent diarrhea and abdominal pain

31
Q

Bulk forming laxative prototype

A

psyllium

32
Q

MOA of psyllium

A

non-digestible agents that swell with water to for a viscous solution that softens and increases stool volume, increasing peristalsis

33
Q

Adverse effects of psyllium

A

must be taken with water to prevent impaction

34
Q

Prototype surfactant laxative

A

docusate sodium

35
Q

MOA of docusate sodium

A

lower surface tension, allow penetration of water

36
Q

Stimulant laxative prototype

A

bisacodyl

37
Q

MOA of bisacodyl

A

stimulates by irritant effects GI motility and increase water and electrolytes in lumen

38
Q

Therapeutic use of bisacodyl

A

widely used, abused
opiod induced constipation
slow intestinal transit constipation

39
Q

Adverse effects of bisacodyl

A

proctitis with long term use

40
Q

Prototype osmotic laxative

A

magnesium hydroxide

41
Q

MOA of magnesium hydroxide

A

poorly absorbed salts or sugars whose osmotic action draws water into the intestinal lumen. causes swelling of stool and stretching of GI wall

42
Q

Therapeutic uses of magnesum hydroxide

A

low dose- group II effect for mild to moderate constipation

high dose-group I effect fluid evacuation of bowel

43
Q

Adverse effects of MgOH

A

can cause dehydration and electrolyte imbalance. Systemic absorption of Mg can cause toxicity

44
Q

Antidiarrheal agents

A

loperamide, diphenoxylate

45
Q

MOA of loperamide and diphenoxylate

A

agonists at myenteric opiate receptors reduces secretory activity (delta) and GI motility (mu)
Loperimide is 50x more potent than morphine

46
Q

Pharmacokinetics of opiod antidiarrheal agents

A

well absorbed orally
Loperamide- poor pentration across the BBB, available OTC
Diphenoxylate- BBB permeable, schedule V, sometimes contain atropine

47
Q

Targets for antiemesis

A

Serotonin acting at 5-HT3 receptors
Dopamine acting at D2 receptors
Substance P/neurokinin 1 (NK1) receptor
Histamine and muscarinic R in vesibular apparatus
glucocorticoid, cannabinoid, GABA and opiod receptors

48
Q

opiod antagonist for opiod induced constipation

A

methylnaltrexone

49
Q

5-HT3 receptor antagonist prototype

A

ondansetron

50
Q

Pharmacokinetics of ondensetron

A

IV, but prophylactic oral, long duration, cleared by CYPs

51
Q

Thereapeutic use of 5-HT3 R antagonists

A

CINV and radiation
pregnancy and postoperative
not effective aginst motion sickness or delayed CINV nausea

52
Q

Adverse effects of 5-HT3R antagonists

A

well-tolerated, constipation/diarrhea, headache

53
Q

Prototype NK1 receptor antagonists

A

aprepitant

54
Q

Pharmacokinetics of aprepitant

A

metabolized by CYP3A4, induces CYP2D6

55
Q

Therapeutic uses of aprepitant

A

delayed nausea, improves efficacy of other agents in CINV

56
Q

Regimen of choice for CINV

A

aprepitant, dexamethasone, 5-HT3 antagonist

57
Q

Treatment for IBS-C

A

dietary fiber (psyllium) and osmotic laxatives

58
Q

Treatment of IBS-D

A

loperamide

59
Q

5-Ht3 R antagonists for IBS-D

A

alsetron

60
Q

MOA of alsetron

A

decreases GI motility and secretions and inhibits unpleasant visceral sensations

61
Q

Therapeutic use of alsetron

A

IBS-D in FEMALE, for severe symptoms lasting longer than 6 months, refractory to all other medications

62
Q

Adverse effects of alsetron

A

severe constipation, life threatening ischemic colitis

63
Q

Mesalamine (5-ASA) based therapy prototype

A

sulfasalazine

64
Q

MOA of sulfasalazine

A

prodrug N=N bond cleaved by intestinal flora to release 5-ASA, which is immune suppressive

65
Q

Adverse effects of sulfasalazine

A

due to metabolite, GI, headaches, arthralgia, myalgia, myelosuppresion

66
Q

Anti-TNF based therapy for IBD

A

inflizimab

67
Q

Side effects of inflizimab

A

injection site and infusion reactions, neutropenia, infection (TB), heart failure, malignancy (lymphomas), pulmonary disease, demyelinating disease, cutaneous reactions, allergic reactions.

Pharmacology (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions